Aspen Sells Ovestin European Rights for €197M
Aspen Pharmacare has agreed to sell European commercialisation rights for its Ovestin product to Ennogen Healthcare International.
Updated on Nov. 2, 2026 in Healthcare
Aspen Pharmacare has sold European commercialisation rights and related intellectual property for Ovestin to Ennogen Healthcare International for €197 million ($220 million). Ennogen will also buy related inventory valued at about €4 million.
Why it matters
The agreement forms part of Aspen's strategy to unlock value from assets outside its core focus on emerging markets. Proceeds will be subject to the company's capital allocation strategy, with share buybacks remaining its preferred method of returning capital to shareholders.
The €197 million sale price compares with Ovestin's 2026 revenue of about 756 million rand ($45 million) and profit after tax of 238 million rand. Details on how the sale proceeds will be allocated have not yet been disclosed.
The players
Aspen Pharmacare
A South African pharmaceutical company that is selling the European commercialisation rights to Ovestin while retaining manufacturing and supply obligations.
Ennogen Healthcare International
The buyer of the European Ovestin commercialisation rights, which will also purchase related inventory and receive support services from Aspen.
The details
Aspen will continue manufacturing and supplying the active pharmaceutical ingredient and cream formulation of Ovestin in Europe for at least 10 years under long-term supply agreements. It will also provide strategic support services to Ennogen for five years for a fee of €1 million per month, plus transitional services for up to three years.
Timeline
2 November 2026: Aspen announced the sale of its Ovestin European rights.
Aspen's 2026 financial year: Ovestin revenue and profit figures were reported.
Over the next three years: Aspen provides transitional services to facilitate the transfer of the business.
Over the next five years: Aspen provides strategic support services to Ennogen.
For at least 10 years: Aspen continues manufacturing and supplying Ovestin in Europe.
Market Landscape
The sale reflects Aspen's continued reshaping of its portfolio toward emerging markets, using divestments of non-core assets to free capital. It positions the company to prioritise share buybacks while retaining a supply role in the European market.
For consumers in Europe, Ovestin will continue to be manufactured and supplied by Aspen under long-term agreements, so availability is expected to be maintained. The change is primarily one of commercial ownership rather than production.
The takeaway
The sale shows how Aspen is redirecting capital from non-core European assets toward its emerging-markets focus and shareholder returns, while keeping a manufacturing role for Ovestin.
Further reading
For more context on the sector, explore Healthcare coverage across South Africa.
